{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:09:43Z","timestamp":1778850583498,"version":"3.51.4"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0895"],"award-info":[{"award-number":["W81XWH-20-1-0895"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jbo.2021.100399","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T03:08:30Z","timestamp":1634872110000},"page":"100399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Ava","family":"Brozovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Garmezy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary C.","family":"Farach-Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Satcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2021.100399_b0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1359\/jbmr.061005","article-title":"TGF-beta promotes the establishment of renal cell carcinoma bone metastasis","volume":"22","author":"Kominsky","year":"2007","journal-title":"J. Bone Min. Res."},{"key":"10.1016\/j.jbo.2021.100399_b0010","doi-asserted-by":"crossref","first-page":"24571","DOI":"10.1074\/jbc.M202561200","article-title":"Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways","volume":"277","author":"Kakonen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2021.100399_b0015","doi-asserted-by":"crossref","first-page":"21352","DOI":"10.1074\/jbc.M111663200","article-title":"Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix","volume":"277","author":"Dallas","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2021.100399_b0020","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2021.100399_b0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0035","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2021.100399_b0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \u201cvicious cycle\u201d paradigm of prostate to bone metastases","volume":"33","author":"Cook","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbo.2021.100399_b0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0050","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2002.20.15.3191","article-title":"Bisphosphonates and tumor burden","volume":"20","author":"Mundy","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0055","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0060","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcb.21835","article-title":"Annexin II\/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer","volume":"105","author":"Shiozawa","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jbo.2021.100399_b0070","doi-asserted-by":"crossref","unstructured":"S.J. Coniglio. Role of tumor-derived chemokines in osteolytic bone metastasis. Front. Endocrinol. (Lausanne) 9, 313, doi:10.3389\/fendo.2018.00313 (2018).","DOI":"10.3389\/fendo.2018.00313"},{"key":"10.1016\/j.jbo.2021.100399_b0075","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0080","doi-asserted-by":"crossref","unstructured":"R. Silbermann. et al. Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 28, 951-954, doi:10.1038\/leu.2013.385 (2014).","DOI":"10.1038\/leu.2013.385"},{"key":"10.1016\/j.jbo.2021.100399_b0085","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, A. Jemal. Cancer statistics, 2020. CA: a cancer journal for clinicians 70 2020 7-30 doi:10.3322\/caac.21590.","DOI":"10.3322\/caac.21590"},{"key":"10.1016\/j.jbo.2021.100399_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amsu.2018.01.002","article-title":"Skeletal metastasis in renal cell carcinoma: a review","volume":"27","author":"Umer","year":"2018","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"10.1016\/j.jbo.2021.100399_b0095","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2021.100399_b0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2021.100399_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0110","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-007-9090-y","article-title":"Renal cell carcinoma bone metastasis\u2013elucidating the molecular targets","volume":"26","author":"Weber","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbo.2021.100399_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbo.2021.100399_b0120","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5312\/wjo.v11.i7.319","article-title":"Current concepts in the surgical treatment of skeletal metastases","volume":"11","author":"Ehne","year":"2020","journal-title":"World J. Orthop."},{"key":"10.1016\/j.jbo.2021.100399_b0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41585-018-0034-9","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"15","author":"Grunwald","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1097-0142(20010815)92:4<761::AID-CNCR1380>3.0.CO;2-#","article-title":"Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study","volume":"92","author":"Kankuri","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0150","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.25750","article-title":"Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy","volume":"117","author":"Heng","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031252","article-title":"The biology of bone metastasis","volume":"8","author":"Esposito","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2214\/ajr.129.1.61","article-title":"Radiographic manifestations of bone metastases from renal carcinoma","volume":"129","author":"Forbes","year":"1977","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.jbo.2021.100399_b0165","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2106\/00004623-200708000-00018","article-title":"Patient survival after surgery for osseous metastases from renal cell carcinoma","volume":"89","author":"Lin","year":"2007","journal-title":"J. Bone Joint Surg."},{"key":"10.1016\/j.jbo.2021.100399_b0170","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2474-11-145","article-title":"Bone metastases from renal cell carcinoma: patient survival after surgical treatment","volume":"11","author":"Fottner","year":"2010","journal-title":"BMC Musculoskelet Disord."},{"issue":"Suppl 2","key":"10.1016\/j.jbo.2021.100399_b0175","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","article-title":"Burden of bone disease","volume":"11","author":"Kinnane","year":"2007","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.jbo.2021.100399_b0180","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0185","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1535-7163.MCT-19-0174","article-title":"Cabozantinib reverses renal cell carcinoma-mediated osteoblast inhibition in three-dimensional coculture in vitro and reduces bone osteolysis in vivo","volume":"19","author":"Pan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbo.2021.100399_b0190","first-page":"1363","article-title":"Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"22","author":"Oster","year":"2014","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0195","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neo.2017.11.002","article-title":"BIGH3 promotes osteolytic lesions in renal cell carcinoma bone metastasis by inhibiting osteoblast differentiation","volume":"20","author":"Pan","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.jbo.2021.100399_b0205","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","article-title":"Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis","volume":"18","author":"Dougall","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00795-013-0064-6","article-title":"Invasion and metastasis of renal cell carcinoma","volume":"47","author":"Mikami","year":"2014","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.jbo.2021.100399_b0215","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/bcr3048","article-title":"Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBFbeta-dependent expression of the Wnt antagonist, sclerostin","volume":"13","author":"Mendoza-Villanueva","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0220","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: the fatal interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0225","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1359\/jbmr.1998.13.4.633","article-title":"Human osteoblasts express a repertoire of cadherins, which are critical for BMP-2-induced osteogenic differentiation","volume":"13","author":"Cheng","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2021.100399_b0230","doi-asserted-by":"crossref","first-page":"12092","DOI":"10.1016\/S0021-9258(17)32685-6","article-title":"Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts","volume":"269","author":"Okazaki","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2021.100399_b0235","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1158\/0008-5472.CAN-09-3016","article-title":"Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0240","first-page":"17","article-title":"Cadherin-11-mediated interactions with bone marrow stromal\/osteoblastic cells support selective colonization of breast cancer cells in bone","volume":"33","author":"Tamura","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089880","article-title":"Cadherin-11 in renal cell carcinoma bone metastasis","volume":"9","author":"Satcher","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbo.2021.100399_b0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clin. Genitourinary Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.2013.272","article-title":"Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study","volume":"109","author":"Alcaraz","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0260","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jbo.2021.100399_b0265","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0270","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jbo.2021.100399_b0285","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0290","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0295","first-page":"79","article-title":"Challenges for 1994 by hospital nursing departments described by directors of nursing. Programs for reaching out to community","volume":"46","author":"Takahashi","year":"1994","journal-title":"Kango"},{"key":"10.1016\/j.jbo.2021.100399_b0300","doi-asserted-by":"crossref","unstructured":"E.A. Eisenhauer. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer (Oxford, England: 1990) 45, 228-247, doi:10.1016\/j.ejca.2008.10.026 (2009).","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.jbo.2021.100399_b0305","doi-asserted-by":"crossref","unstructured":"H. Deng et al. Comparative Efficacy, Safety, and costs of sorafenib vs. sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis. Front. Oncol. 9 479, doi:10.3389\/fonc.2019.00479 (2019).","DOI":"10.3389\/fonc.2019.00479"},{"key":"10.1016\/j.jbo.2021.100399_b0310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","article-title":"Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases","volume":"136","author":"Zolnierek","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-017-0004-5","article-title":"mTOR signaling in skeletal development and disease","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.jbo.2021.100399_b0320","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12885-015-1717-8","article-title":"Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells","volume":"15","author":"Simone","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111827","article-title":"The effect of everolimus in an in vitro model of triple negative breast cancer and osteoclasts","volume":"17","author":"Mercatali","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2021.100399_b0330","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1073\/pnas.93.15.7644","article-title":"Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro","volume":"93","author":"Grano","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.jbo.2021.100399_b0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40267-018-0547-6","article-title":"Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use","volume":"34","author":"Lyseng-Williamson","year":"2018","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.jbo.2021.100399_b0340","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.04.031","article-title":"Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors","author":"Haaker","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0350","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0355","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus Everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020203","article-title":"The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy","volume":"8","author":"Botticelli","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jbo.2021.100399_b0365","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.jbo.2021.100399_b0370","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0022-5347(05)67016-4","article-title":"Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention","volume":"164","author":"Kollender","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0375","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-5347(17)60797-3","article-title":"Cryosurgery in the treatment of solitary or multiple bone metastases from renal cell carcinoma","volume":"108","author":"Marcove","year":"1972","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0380","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2106\/JBJS.H.00175","article-title":"Surgical management of metastatic bone disease","volume":"91","author":"Bickels","year":"2009","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.jbo.2021.100399_b0385","doi-asserted-by":"crossref","unstructured":"S. D'Oronzo, R. Coleman, J. Brown, F. Silvestris. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J. Bone Oncol. 15 2019 004-004, doi:10.1016\/j.jbo.2018.10.004.","DOI":"10.1016\/j.jbo.2018.10.004"},{"key":"10.1016\/j.jbo.2021.100399_b0390","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2021.100399_b0395","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0400","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0405","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2021.100399_b0410","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2021.100399_b0415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0420","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0425","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2021.100399_b0430","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0435","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000000290","article-title":"Targeted \u03b1-particle therapy of bone metastases in prostate cancer","volume":"38","author":"Jadvar","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0440","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0445","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0450","doi-asserted-by":"crossref","unstructured":"P.G. Kluetz et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 20, 9-14, doi:10.1158\/1078-0432.ccr-13-2665 (2014).","DOI":"10.1158\/1078-0432.CCR-13-2665"},{"key":"10.1016\/j.jbo.2021.100399_b0455","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0460","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0465","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.jbo.2021.100399_b0475","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0480","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jbo.2021.100399_b0485","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jbo.2021.100399_b0490","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0495","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0500","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative, G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386 2015 1353-1361, doi:10.1016\/S0140-6736(15)60908-4 (2015).","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"10.1016\/j.jbo.2021.100399_b0505","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1038\/s41388-019-0736-3","article-title":"Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jbo.2021.100399_b0510","doi-asserted-by":"crossref","unstructured":"Coleman, R. et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann. Oncol.: official journal of the European Society for Medical Oncology\/ESMO 25 Suppl 3 2014 iii124-137, doi:10.1093\/annonc\/mdu103.","DOI":"10.1093\/annonc\/mdu103"},{"key":"10.1016\/j.jbo.2021.100399_b0515","first-page":"35","article-title":"Reproducibility of guidelines. A comparison of the NCCN and ASCO lung cancer guidelines","volume":"13","author":"Winn","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jbo.2021.100399_b0520","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0525","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0535","first-page":"2985","article-title":"Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis","volume":"20","author":"Lopez-Olivo","year":"2012","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0540","first-page":"752","article-title":"Clinical evaluation of combined-modality therapy for bone metastasis of non-small-cell lung cancer","volume":"23","author":"Li","year":"2003","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"10.1016\/j.jbo.2021.100399_b0545","first-page":"357","article-title":"(8)(9)SrCl(2) and\/or Bonefos in the treatment of bone metastasis from pulmonary carcinoma","volume":"5","author":"Su","year":"2002","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.jbo.2021.100399_b0550","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2009.03.017","article-title":"Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study","volume":"67","author":"Zhang","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0555","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","article-title":"Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer","volume":"67","author":"Pandya","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0560","first-page":"656","article-title":"Characteristics and treatment of bone metastases in 322 cases non-small cell lung cancer: a retrospective study","volume":"17","author":"Guo","year":"2014","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.jbo.2021.100399_b0565","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12885-019-5445-3","article-title":"Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2021.100399_b0570","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0575","first-page":"23","article-title":"The key role of bisphosphonates in the supportive care of cancer patients","volume":"34","author":"Tolia","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbo.2021.100399_b0580","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.jbo.2021.100399_b0585","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann. Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:31:25Z","timestamp":1778848285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137421000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":117,"alternative-id":["S2212137421000543"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100399","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100399"}}